- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06107439
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects (LIPOKINES)
October 27, 2023 updated by: Centre Hospitalier Universitaire de la Réunion
Few data and small numbers affect the inflammatory profile of Dunnigan patients.
The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals.
However, in these studies, several confounding factors were not taken into account such as smoking, an underlying chronic inflammatory disease such as diabetes and could limit the interpretation of the results.
There is no other observation of the anti-inflammatory status of these patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Saint-Pierre, Réunion, 97400
- Recruiting
- CHU La Réunion DRCI
-
Contact:
- mathilde SIMONSON
- Phone Number: 0262359000
- Email: mathilde.simonson@chu-reunion.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult subject (>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study).
- Person affiliated to or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant and the investigator.
Exclusion Criteria:
- - Minor
- Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study
- Previous known diabetes
- Pregnant woman
- Woman who gave birth less than 6 months ago
- Breastfeeding in progress
- Participation in other research that may have an impact on the evaluation of the main judgment criteria
- Hemoglobin b level < 7 mg/dl or < 9-10 mg/dl for patients with cardiovascular or respiratory pathology.
- Proven inflammatory pathologies
- Anti-inflammatory treatment: taking corticosteroids in the last 3 months.
- Active smoking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: sampling and clinical data collection
Participant blood and urine are sampled for inflammatory signal analysis
|
Bood and urine sampling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pro-inflammatory markers
Time Frame: inclusion day
|
blood sample and dosage of pro inflammatory cytokine
|
inclusion day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2023
Primary Completion (Estimated)
August 13, 2024
Study Completion (Estimated)
August 13, 2025
Study Registration Dates
First Submitted
September 14, 2023
First Submitted That Met QC Criteria
October 27, 2023
First Posted (Actual)
October 30, 2023
Study Record Updates
Last Update Posted (Actual)
October 30, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021/CHU/12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipodystrophy
-
Aegerion Pharmaceuticals, Inc.RecruitingPartial Lipodystrophy | Generalised LipodystrophyUnited States, Germany, Italy
-
University Hospital, LilleRecruitingFamilial Partial Lipodystrophy Type 2France
-
Amryt PharmaRecruitingPartial LipodystrophyUnited States, Canada
-
University of UlmUniversity of Pisa; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaboratorsRecruitingLipodystrophy Acquired | Lipodystrophy CongenitalAustria, France, Germany, Hungary, Italy, Portugal, Spain, Netherlands, Russian Federation, Slovenia, Switzerland, Turkey, United Kingdom
-
Regeneron PharmaceuticalsAvailablePartial Lipodystrophy | Generalized Lipodystrophy | Monogenic Obesity Due to LEP or LEPR Loss of Function
-
University of Texas Southwestern Medical CenterCompletedInsulin Resistance | Partial Lipodystrophy | Generalized Lipodystrophy | HypoleptinemiaUnited States
-
Regeneron PharmaceuticalsActive, not recruitingGeneralized LipodystrophyUnited States, Peru, Russian Federation, Turkey
-
University of MichiganAvailable
-
Mayo ClinicCompleted
-
Escola Superior de Tecnologia da Saúde do PortoCompleted
Clinical Trials on Bood and urine sampling
-
Centre Hospitalier Universitaire de CharleroiUniversité Catholique de LouvainUnknownBacterial Infections | Renal Failure Chronic Requiring Hemodialysis | Ceftazidime
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Mesenteric IschemiaFrance
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustUnknownLipoma of Spinal CordUnited Kingdom
-
University Hospital, LimogesRecruiting
-
University Hospital, ToulouseRecruiting
-
University Hospital Inselspital, BerneCompletedKidney Transplantation | Delayed Graft FunctionGermany, Switzerland
-
Centre Hospitalier Universitaire de Saint EtienneWithdrawnAnorexia Nervosa | Eating DisorderFrance
-
Chang Gung Memorial HospitalChang Gung UniversityUnknown